Modality
Fusion Protein
MOA
IL-23i
Target
CD38
Pathway
DDR
MCLACC
Development Pipeline
Preclinical
~May 2016
→ ~Aug 2017
Phase 1
~Nov 2017
→ ~Feb 2019
Phase 2
May 2019
→ Jun 2030
Phase 2Current
NCT06820996
685 pts·MCL
2024-09→2030-06·Recruiting
NCT04185806
2,510 pts·ACC
2019-05→2028-06·Terminated
3,195 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-06-152.2y awayPh2 Data· ACC
2030-06-104.2y awayPh2 Data· MCL
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2
Termina…
P2
Recruit…
Catalysts
Ph2 Data
2028-06-15 · 2.2y away
ACC
Ph2 Data
2030-06-10 · 4.2y away
MCL
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06820996 | Phase 2 | MCL | Recruiting | 685 | eGFR |
| NCT04185806 | Phase 2 | ACC | Terminated | 2510 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Ivosotorasib | Vertex Pharma | Preclinical | CD38 |